SUMMARY One hundred patients with benign gastric ulceration were treated in a single-blind, endoscopically controlled trial to assess the relative efficacy of cimetidine (1 g daily) and Caved-S (six tablets daily). Ulcer healing was assessed after six weeks' treatment, and, if incomplete, after a further six weeks. There was no significant difference between the two drug regimens (approximately 63% at six weeks and 91% at 12 weeks). If an ulcer remains unhealed after 12 weeks' treatment the patient should undergo surgery. There was no difference in the relief of day pain between the two drug regimens but cimetidine was more effective over the first two weeks of treatment in relieving night pain, than was Caved-S (p<002). After ulcer healing, drug dosage was reduced (cimetidine to 400 mg at night and Caved-S to two tablets twice daily). So far, 56 patients, 28 in each group, have completed the first year's maintenance treatment, and there have been four ulcer recurrences in each group (14%).
provides acute services for a population of approximately 160 000, a completely unselected group of patients was thus entered into the study.
HEALING STUDY
Drug treatment and dosage The nature of the trial was fully explained to the patients before entry and their informed consent obtained in accordance with the Declaration of Helsinki. They were then randomly allocated (single-blind) to treatment with either Caved-S, deglycyrrhizinated liquorice plus antacid combination, two tablets to be chewed three times a day between meals or cimetidine 200 mg three times a day and 400 mg at night. All patients were given antacids (Rennies) to take as required. A personal diary card was completed recording severity of 545 symptoms, the number of antacids taken, and drug compliance. Treatment was continued for up to 12 weeks.
Method for random allocation The choice of treatment for each patient was determined using tables of random numbers. The chosen regimen was then placed in sealed envelopes numbered one to 100 by a colleague not involved in the study.
Initial investigations and follow-up Endoscopy was performed on all patients at the start of the study and after six weeks' treatment. If healing was incomplete, a further six weeks' treatment was prescribed and endoscopy repeated after a total of 12 weeks' therapy. All ulcers were biopsied to exclude an ulcer cancer. Ulcer healing was defined as complete disappearance of ulceration or erosion. Ulcer size was usually assessed using an ACMI endoscopic measuring gauge or the open biopsy forceps. Treatment was considered to have failed when an ulcer remained unhealed after three months' treatment or the patient was withdrawn from the trial because of complications or failure to control symptoms.
A safety screening programme, including haematological, biochemical, and clinical parameters, was carried out at the time of each endoscopy.
MAINTENANCE STUDY
Once ulcer healing had been achieved, all those patients who were fit enough were entered into a two year maintenance study. The dose of cimetidine was reduced to 400 mg at night and that of Caved-S to two tablets twice a day. All patients were reviewed in the outpatient department at three monthly intervals and the safety screening programme was repeated at six monthly intervals. The patients and general practitioners were asked to report any recurrence of dyspeptic symptoms between outpatient visits, so that endoscopy could be done within a few days to check for a possible ulcer recurrence. After six months' maintenance therapy, a routine barium meal examination was performed to seek an asymptomatic ulcer recurrence.
Statistical methods
The chi square test was used for groups with large numbers, and the binomial test for small numbers. The pain score data were analysed after logarithmic transformation and the regression coefficients compared using Student's t test on pairs of the mean value.
Results

HEALING STUDY
The treatment groups were evenly matched for all parameters analysed (Table 1 ). There was no statistical difference in the healing rates for the two drug regimens. Approximately 63% of all ulcers were healed at six weeks and 91% after 12 weeks' treatment ( The patients included in this study are completely unselected and represent almost the total yield of gastric ulcers presenting to the Department of Radiology and the Endoscopic Unit over a threeyear period. One hundred and seventeen patients were initially entered into the study. Six patients were withdrawn because the initial endoscopic biopsy showed cancer and in a further patient this was picked up by a biopsy taken after six weeks' therapy. The endoscopic appearance taken with the biopsy of an ulcer aids recognition of an ulcer cancer,4 and we feel therefore that the treatment period can safely be extended to 12 weeks. The importance, however, of endoscopic biopsy of all gastric ulcers is emphasised by two of our patients who were treated with cimetidine. Their symptoms disappeared and their ulcers healed but biopsies detected carcinoma, later confirmed at laparotomy. These two cases are similar to others in the literature on cimetidine therapy in which both the healing of ulcer cancers and relief of dyspeptic symptoms occurred,5 and two others we have met ourselves, which are not in this study.
The true incidence of drug-induced gastric ulcer is still much debated, as the evidence for this association is very slender.6 Cooke and Thompson7 have recently reviewed the medication taken by 202 patients admitted with gastric ulcer to the Bristol Royal Infirmary between 1974-78, and found that 18% were on a non-steroidal anti-inflammatory drug (NSAD). In our study, such drug therapy is also an important contributing factor, as 19 out of the 100 patients were receiving treatment before diagnosis (four on steroids and 15 on NSAD). Fifteen were admitted with acute gastrointestinal bleeding (78%) but only two patients had later to be withdrawn from the study because of continued bleeding (8%). This low incidence of continuing bleeding or rebleeding requiring surgical intervention contrasts with other studies that have shown that from 21% to 42% come finally to surgery."11
The healing rate of 66% after six weeks' cimetidine therapy is in line with the results obtained by previous workers using cimetidine.12 16 It is a rather low healing rate compared with the results of duodenal ulcer treatment but it can be improved by a further six weeks' therapy when 94% of all ulcers are healed. Caved-S produced a slightly lower healing rate (60% at six weeks and 88% at 12 weeks) but this did not reach statistical significance.
Follow-up of the nine patients with ulcers unhealed after 12 weeks' treatment showed that neither continuing nor changing the treatment was very successful in producing further ulcer healing. We therefore recommend that if an ulcer remains unhealed after 12 weeks' treatment the patient should undergo surgery.
Ciclitera in 1977 showed that cimetidine was more effective than placebo in relieving the pain associated with gastric ulceration. In this study the level of symptoms in the two treatment groups was evenly matched for both day and night pain in the pre-treatment week. After treatment began there was a rapid decline in pain scores of both day and night pain. In the first two weeks cimetidine caused the night pain score to fall more rapidly than did Caved-S. This may be explained by the fact that the last dose of cimetidine is given just before retiring and Caved-S was not given at night. There was no other statistical difference between the two drugs.
No clinically significant side-effects were encountered, although safety screening picked up two transient rises in liver enzymes in patients on cimetidine, these settled without having to discontinue therapy. In any long-term drug therapy, it is important to look for possible side-effects .from chronic ingestion of the drug. Caved-S used to contain, as well as deglycyrrhizinated liquorice and a mixture of antacids, bismuth subitrate (withdrawn in 1980).
In both France and Australia, encephalopathy has been reported as a complication of taking large doses of bismuth salts (5 to 25 g per day). 18 19 The total daily dose in this study is 400 mg and at this dosage no clinical trial worker has encountered any such problems.
It has been debated for some time whether long-term cimetidine therapy may result in an increased risk of gastric cancer.20 This could occur by the conversion within the stomach of cimetidine into a nitrozo derivative, but long-term animal studies have shown no such malignant potential. Likewise, the hypochlorhydria produced by cimetidine could result in bacterial colonisation and intragastric formation of N-nitrosoma compounds which are known to be carcinogenic. It has, however, been shown that sustained bacterial colonisation rarely occurs during maintenance cimetidine therapy and that the levels of nitrate in gastric juice are rarely raised.21 Any possible longterm risks of drug therapy must also be balanced against the knowledge that a partial gastrectomy has a very definite mortality in those older patients with gastric ulcers, and that a partial gastrectomy itself increases the risk of gastric cancer.22
The effectiveness of Caved-S in the treatment of gastric ulceration as shown in this study confirms the results obtained in our previous trial.2 This, however, contrasts with the trial published by Bardhan et a!23 in which they compared Ulcedal with placebo and could find no difference in the rate of gastric ulcer healing. They therefore concluded that 'deglycyrrhizinated liquorice has no continuing place in clinical practice'. These conflicting results are, at first sight, difficult to understand, as both Ulcedal and Caved-S contains deglycyrrhizinated liquorice (DGL) prepared by the same manufacturer. In Ulcedal the liquorice is then packed in a gelatin capsule and is swallowed whole, whereas in Caved-S it has to be chewed. We believe that it is this difference in formulation that has produced these conflicting results. Although the gelatin capsule does disintegrate within the stomach, the liquorice does not break up and disperse, but passes through intact into the small bowel.
To achieve gastric ulcer healing the liquorice must be partly released within the stomach and absorbed through the gastric mucosa. 24 The liquorice in Ulcedal would appear to be released and presumably absorbed lower down in the gastrointestinal tract. Deglycyrrhizinated liquorice has been shown in animals to protect the gastric mucosa from the damaging effect of both aspirin and bile.2927 If, however, deglycyrrhizinated liquorice and cimetidine are used together, the combination is more effective in reducing aspirin-induced mucosal damage than either drug used alone.28
In this study we have confirmed that Caved-S is as effective as cimetidine in gastric ulcer therapy. We therefore suggest that the combination of a histamine H2 antagonist and Caved-S should be tried to see if the rate of gastric ulcer healing can be further accelerated.
MAINTENANCE STUDY
That gastric ulcers tend to recur rapidly after healing is well documented.29 30 So far, in the present study 28 patients in each subgroup have completed one year or more of maintenance treatment, and there had been four ulcer recurrences during the first year in each subgroup (14%).
Maintenance treatment with either Caved-S or cimetidine does not appear to reduce the incidence of early relapse (first six months), but is more successful in reducing late recurrences (six to 12 months) (Fig. 2) . It would be interesting to see if this early relapse could be reduced by continuing the full initial dosage for a further six weeks or so after healing is endoscopically complete.
The overall recurrence rate is similar to the two English studies of cimetidine versus placebo so far published, in which 800 mg and 1 g of cimetidine per day were used.31 32 Slightly better results have been obtained in studies from Denmark and Australia33 35 but the number of patients in each treatment group of all the studies is rather small.
In the second year of our maintenance treatment, there have been nine further ulcer recurrences, giving a total recurrence rate of 30%. As this second year's follow-up is still incomplete, the final figure may be even higher. Single drug therapy appears, therefore, to delay rather than prevent gastric ulcer recurrence.
